Part A: Placebo

DRUG2 trials

Sponsors

Cara Therapeutics, Inc., GlaxoSmithKline

Conditions

Idiopathic Pulmonary FibrosisPruritusUremic Pruritus

Phase 1

A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib

CompletedNCT06625489

GlaxoSmithKlineIdiopathic Pulmonary Fibrosis

Start: 2024-10-07End: 2024-11-25Updated: 2025-02-18

Phase 2

Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

CompletedNCT02229929

Cara Therapeutics, Inc.Pruritus, Uremic Pruritus

Start: 2014-07-31End: 2015-07-31Updated: 2016-08-10

Related Papers

Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus

BMC Nephrology2024-10-142 citations

Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program

Kidney Medicine2022-06-2847 citations